|
| Investigators showed a DNA methylation signature for HCC detection in liquid biopsies, distinct from normal tissues and blood profiles. [Nature Communications] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Single-nucleus RNA sequencing analysis revealed pathways involved in fatty acid oxidation in DNA methyltransferases (Dnmt1)-deficient hepatocytes. [Advanced Science] |
|
|
|
| Herein investigators found that ferroptosis inducers sorafenib and erastin could enhance cuproptosis in primary liver cancer cells by increasing copper dependent lipoylated protein aggregation. [Journal Of Experimental & Clinical Cancer Research] |
|
|
|
| The efficient downregulation of autophagy-related gene 7 led to an excellent antifibrotic effect both in vitro and in vivo. [ACS Applied Materials & Interfaces] |
|
|
|
| Scientists used label-free Raman microscopy to assess human induced pluripotent stem cell differentiation into hepatocyte lineage based on the intracellular chemical content. [Analytical Chemistry] |
|
|
|
| The authors observed the histopathological features of the progression of NASH to liver fibrosis as well as hepatocyte epithelial-mesenchymal transition in a mouse model of NASH with type 2 diabetes mellitus, and high-glucose-cultured steatotic human normal liver cells. [Cell Death Discovery] |
|
|
|
| In view of the key metabolic role of tribbles related homolog 1 (TRIB1) and the impact of proteasome inhibition on hepatic function, researchers explored TRIB1 regulation in two commonly used human hepatocyte models, transformed cell lines HuH-7 and HepG2. [Scientific Reports] |
|
|
|
| The expression of Y-box binding protein 1 in human liver microarray, mice tissues, and primary mouse hepatic stellate cells was validated to be upregulated in several hepatic fibrosis models. [Cellular Signalling] |
| |
|
|
|
| The authors discuss why antifibrotic effects observed in NASH pharmacotherapy trials have been underwhelming and outline potential approaches to improve the likelihood of future clinical success. [Nature Reviews Gastroenterology & Hepatology] |
|
|
|
| Scientists cover the molecular, cellular and organismal aspects of various liver pathologies from a circadian viewpoint, and in particular how circadian dysregulation has a role in the development and progression of these diseases. [Nature Reviews Gastroenterology & Hepatology] |
|
|
|
| The authors outline the differentiation system of liver non-parenchymal cells from human induced pluripotent stem celld (hiPSCs) and development of in vitro liver disease models using hiPSC-derived liver cells. [Biochemical Society Transactions] |
|
|
|
|
| The California Institute for Regenerative Medicine (CIRM) awarded Eureka Therapeutics, Inc. a $10.6 million grant to support its ongoing ARYA-2 Phase I study of ET140203 for the treatment of pediatric patients with refractory/relapsed liver cancer. [Eureka Therapeutics, Inc.] |
|
|
|
|
| June 28 – July 1, 2023 Barcelona, Spain |
|
|
|
|
|
| Cincinnati Children’s Hospital Medical Center – Cincinnati, Ohio, United States |
|
|
|
| University of New South Wales – Sydney, New South Wales, Australia |
|
|
|
| Centre for Oncology and Immunology – Hong Kong, Hong Kong |
|
|
|
| University of Geneva – Geneva, Switzerland |
|
|
|
| University of Utah – Salt Lake City, Utah, United States |
|
|
|
|